{
    "nct_id": "NCT00018382",
    "title": "Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach",
    "status": "COMPLETED",
    "last_update_time": "2009-01-20",
    "description_brief": "This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "rosiglitazone",
        "sitagliptin (listed as co-intervention)"
    ],
    "placebo": [
        "placebo (randomized, double\u2011blind design implied)"
    ],
    "explanation_target": [
        "Reason: The study description states it examines \"insulin\u2011sensitizing compounds\" as therapeutic agents for cognitive impairment in Alzheimer's disease; that indicates an intervention aiming to modify disease-related metabolic/pathologic processes (insulin resistance) rather than only symptomatic cognitive enhancement or neuropsychiatric symptom control. \ue200cite\ue202turn1search1\ue202turn1search6\ue201",
        "Act: The trial record (NCT00018382, \"Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach\") lists rosiglitazone as the drug intervention and also mentions sitagliptin in the interventions listing. Rosiglitazone is a thiazolidinedione PPAR\u2011gamma agonist \u2014 an oral small\u2011molecule insulin sensitizer \u2014 which matches the description's class. \ue200cite\ue202turn1search1\ue202turn1search6\ue202turn0search8\ue201",
        "Web search results (key sources found):",
        "- Trial record / trial summary listing title, phase, and interventions (rosiglitazone; sitagliptin). \ue200cite\ue202turn1search1\ue202turn1search2\ue201",
        "- RxWiki / trial summary also lists rosiglitazone for NCT00018382. \ue200cite\ue202turn1search6\ue201",
        "- Reviews and preclinical/clinical literature describing rosiglitazone as an insulin sensitizer (PPAR\u03b3 agonist) investigated for cognitive/Alzheimer effects. \ue200cite\ue202turn0search8\ue202turn0search4\ue201",
        "Reflect: Because the intervention is an oral small\u2011molecule insulin sensitizer (rosiglitazone) intended to target insulin resistance-related pathogenic mechanisms in AD, the appropriate category is \"disease-targeted small molecule.\" Sitagliptin (a DPP\u20114 inhibitor) appeared in the trial listing as a co\u2011intervention in some records but is an incretin/antidiabetic small molecule rather than a biologic; either way these are small\u2011molecule metabolic agents, not biologics or purely symptomatic cognitive enhancers. I therefore classify the trial as disease\u2011targeted small molecule. \ue200cite\ue202turn1search1\ue202turn1search6\ue202turn0search8\ue201",
        "Notes / ambiguity: The publicly available trial summaries for NCT00018382 are sparse (limited detail in the record) so the exact treatment arms/doses/outcomes are not fully described in those summaries; however multiple trial registries and summaries clearly list rosiglitazone as the primary insulin\u2011sensitizing investigational drug. If you want, I can fetch the original ClinicalTrials.gov page or archived records (or look for any published results) to extract more specifics (dosing, comparator, endpoints). \ue200cite\ue202turn1search1\ue202turn1search2\ue201"
    ],
    "agent_type": "J) Metabolism and Bioenergetics",
    "explanation_agent": [
        "Reason: The trial tests insulin\u2011sensitizing small molecules (rosiglitazone; sitagliptin listed as co\u2011intervention) to modify insulin resistance/brain metabolic pathways implicated in Alzheimer\u2019s disease, so the biological focus is metabolic/bioenergetic mechanisms rather than amyloid, tau, or purely symptomatic neurotransmitter targets. \ue200cite\ue202turn0search0\ue201",
        "Act: The clinical record NCT00018382 lists rosiglitazone (a thiazolidinedione PPAR-\u03b3 agonist, an oral insulin sensitizer) and sitagliptin (a DPP\u20114 inhibitor that raises GLP\u20111 signaling) as interventions; both drug classes act on systemic/brain insulin signaling and metabolic pathways. \ue200cite\ue202turn0search0\ue202turn0search4\ue202turn0search3\ue201",
        "Reflect: Mapping to CADRO, these interventions best fit category J) Metabolism and Bioenergetics because they target insulin signaling and related metabolic processes in AD. No evidence in the trial description indicates a primary amyloid-, tau-, inflammatory- or synaptic\u2011only target, so J is the most specific CADRO match. (If additional trial details showed a multi-mechanistic biologic focus, R) Multi\u2011target could be considered, but available records support J.) \ue200cite\ue202turn0search0\ue202turn0search5\ue201",
        "Web search results (key sources):",
        "- Clinical trial record NCT00018382 listing title, phase and interventions (rosiglitazone; sitagliptin). \ue200cite\ue202turn0search0\ue201",
        "- Preclinical/clinical literature describing rosiglitazone as a PPAR\u2011\u03b3 agonist that modulates insulin sensitivity and can affect amyloid/tau and neuroinflammation in AD models. \ue200cite\ue202turn0search4\ue202turn0search6\ue201",
        "- Studies of sitagliptin (DPP\u20114 inhibitor) showing effects on GLP\u20111 signaling, neuroprotection and cognitive outcomes in preclinical and clinical reports. \ue200cite\ue202turn0search2\ue202turn0search3\ue201"
    ]
}